Compare Amgen, Inc. (AMGN) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Johnson Controls International PLC — how do they compare? Amgen, Inc. trades at $415.41 (market cap $224.14B), while Johnson Controls International PLC trades at $154.53 (market cap $93.74B). The key difference: Amgen, Inc. is far larger — about 2.4× Johnson Controls International PLC's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | JCI | |
|---|---|---|
Market Cap | $224.14B | $93.74B |
Sector | Health | Industrials |
52-Week High | $417.20 | $154.76 |
52-Week Low | $271.18 | $103.52 |
Enterprise Value | $267.45B | $102.58B |
Dividend Yield | 2.43% | 1.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
Johnson Controls International (JCI) trades at $154.06, up 2.23% on the day, with a bullish technical signal from moving averages and strong recent earnings beats. The company reported robust Q3 2026 results with organic sales growth of 10% and raised its full-year guidance, driven by demand for data-center thermal management systems. Valuation ratios are elevated, with a P/E of 43.59 and P/S of 3.82, reflecting growth expectations. The stock is near its pivot point of $154, with immediate resistance at $155.
The outlook for JCI is positive, supported by strong operational momentum and strategic positioning in energy-efficient building solutions. Key opportunities include expanding AI-related cooling demand and consistent earnings outperformance. Risks involve high valuation multiples, increasing debt-to-asset ratios, and potential macroeconomic pressures on construction markets. Analyst consensus remains strongly bullish with a $168.25 price target, though investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
